Menu

Impact Events

More
Date Lead Company Event Type Approval Change Approval Likelihood
6/7/26 Eli Lilly and Company (LLY) Xinermei for Obesity Subscribers Only Subscribers Only Subscribers Only
6/7/26 Eli Lilly and Company (LLY) Xinermei for Diabetes Mellitus, Type II Subscribers Only Subscribers Only Subscribers Only
6/7/26 Boehringer survodutide for Obesity Subscribers Only Subscribers Only Subscribers Only
6/5/26 Gan & Lee Pharmaceuticals GZR-4 for Diabetes Mellitus, Type II Subscribers Only Subscribers Only Subscribers Only
6/5/26 Zealand Pharma (ZEAL) petrelintide for Obesity Subscribers Only Subscribers Only Subscribers Only

Upcoming Catalysts

More
Expected Date Range Lead Company Drug Expected Catalyst
03/31/2023 Subscribers Only Subscribers Only Trial Announcement - Initiation
06/25/2025 Subscribers Only Subscribers Only Company - Analyst/R&D Update
06/25/2025 Subscribers Only Subscribers Only Company - Analyst/R&D Update
06/26/2025 Subscribers Only Subscribers Only Company - Analyst/R&D Update
09/08/2025 Subscribers Only Subscribers Only Company - Analyst/R&D Update